Moderna's mFlusvia Under Scrutiny
A significant development in influenza prevention is currently under consideration by US health authorities. An advisory committee to the Food and Drug Administration (FDA) is examining a groundbreaking flu vaccine developed by Moderna, known as mFlusvia. This vaccine is particularly notable as it incorporates mRNA technology, the same innovative approach that played a crucial role in combating the COVID-19 pandemic.
Targeting Older Adults
Moderna is seeking FDA approval for mFlusvia specifically for use in individuals aged 50 and older. The ongoing FDA advisory committee meeting represents a pivotal stage in the regulatory process, moving towards a final determination before the upcoming winter flu season. The potential approval of mFlusvia could introduce a new option for influenza protection for this demographic.
Source: Original Article